SCHEMBL16786353

SCHEMBL16786353

CC[C@H](C)n1nc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EZH2 Q15910 17/20 1.00
EZH1 Q92800 6/20 0.79
EED O75530 2/20 0.79
SUZ12 Q15022 2/20 0.79
HDAC1 Q13547 2/20 0.63
RBBP4 Q09028 1/20 0.63
RBBP7 Q16576 1/20 0.63
AEBP2 Q6ZN18 1/20 0.63
HDAC6 Q9UBN7 2/20 0.60
HDAC4 P56524 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC2 Q92769 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180731 0.94 EZH2 (0.88) EZH2EZH1EEDSUZ12HDAC1
Hydrochloric Acid SCHEMBL2590277 0.93 EZH2 (0.87) EZH2EZH1EEDSUZ12HDAC1
Gsk2816126 SCHEMBL12180401 0.88 EZH2 (1.00) EZH2EZH1EEDSUZ12HDAC1
Gsk2816126 SCHEMBL2595737 0.88 EZH2 (1.00) EZH2EZH1EEDSUZ12HDAC1
Gsk2816126 SCHEMBL2593705 0.88 EZH2 (1.00) EZH2EZH1EEDSUZ12HDAC1
Gsk2816126 SCHEMBL29352969 0.88 EZH2 (1.00) EZH2EZH1EEDSUZ12HDAC1
SCHEMBL2585424 0.87 EZH1 (0.80) EZH2EZH1EEDSUZ12RBBP4
SCHEMBL2590359 0.87 EZH2 (0.78) EZH2EZH1EEDSUZ12HDAC1
SCHEMBL18768926 0.85 EZH2 (0.88) EZH2EZH1EEDSUZ12HDAC1
SCHEMBL2594075 0.84 EZH2 (1.00) EZH2EZH1EEDSUZ12HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193084-A1 INHIBITORS OF EZH2 AND METHODS OF USE THEREOF Epizyme, Inc. 2022-06-23 US disclosed
US-20150160246-A1 DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS ANALIZA, INC. (US) 2015-06-11 US disclosed
US-20150160246-A1 DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS ANALIZA, INC. (US) 2015-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193084-A1 INHIBITORS OF EZH2 AND METHODS OF USE THEREOF EZH2, EZH1, BMI1 EZH2 1/4885EZH1 2/4885EED 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.